SCHEMBL2015934

SCHEMBL2015934

Cln1c2cnccc2c2cccnc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKE Q14164 3/20 0.40
TBK1 Q9UHD2 3/20 0.40
PDPK1 O15530 2/20 0.40
TGFBR1 P36897 2/20 0.40
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
HDAC2 Q92769 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
KDM4C Q9H3R0 3/20 0.36
MAOA P21397 5/20 0.35
MAOB P27338 5/20 0.35
ACHE P22303 1/20 0.35
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
FEN1 P39748 1/20 0.34
KDM4E B2RXH2 2/20 0.34
KDM5A P29375 2/20 0.34
KDM6B O15054 1/20 0.34
KDM5B Q9UGL1 1/20 0.33
ROCK2 O75116 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2628325 0.83 PDPK1 (0.46) IKBKETBK1PDPK1TGFBR1KDM4C
SCHEMBL16011813 0.82 HDAC1 (0.43) HDAC2HDAC6ACHEHDAC3HDAC1
SCHEMBL18381816 0.80 PDPK1 (0.44) IKBKETBK1PDPK1TGFBR1MAOA
SCHEMBL16640342 0.76 CDK4 (0.41) IKBKETBK1PDPK1TGFBR1DDB1
SCHEMBL11910143 0.74 PDE4A (0.39) IKBKETBK1PDPK1TGFBR1DDB1
SCHEMBL2628361 0.72 TOP2A (0.47) IKBKETBK1PDPK1TGFBR1DDB1
SCHEMBL21917540 0.72 MAOA (0.39) IKBKETBK1PDPK1TGFBR1DDB1
SCHEMBL12759666 0.71 MAOA (0.37) IKBKETBK1PDPK1TGFBR1HDAC2
SCHEMBL12165648 0.71 NPC1 (0.37) IKBKETBK1PDPK1TGFBR1DDB1
SCHEMBL13932200 0.70 KDM4E (0.41) MAOAMAOBACHEFEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513110-B1 1,7-DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER HOFFMANN LA ROCHE (CH) 2018-12-05 EP disclosed
US-9440976-B2 1,7-diazacarbazoles and methods of use GENENTECH, INC. (US) 2016-09-13 US disclosed
US-20150328195-A1 1,7-DIAZACARBAZOLES AND METHODS OF USE GENENTECH, INC. (US) 2015-11-19 US disclosed
US-20140171407-A1 1,7-DIAZACARBAZOLES AND METHODS OF USE GENENTECH, INC. (US) 2014-06-19 US disclosed
EP-2513110-A1 1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
US-20110183938-A1 1,7-DIAZACARBAZOLES AND METHODS OF USE GENENTECH, INC. (US) 2011-07-28 US disclosed
WO-2011073263-A1 1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150328195-A1 1,7-DIAZACARBAZOLES AND METHODS OF USE CHEK1, CHEK2, BUB1B IKBKE 153/4885TBK1 392/4885PDPK1 36/4885
US-20110183938-A1 1,7-DIAZACARBAZOLES AND METHODS OF USE CHEK1, CHEK2, BUB1B IKBKE 153/4885TBK1 392/4885PDPK1 36/4885
US-20140171407-A1 1,7-DIAZACARBAZOLES AND METHODS OF USE CHEK1, CHEK2, BUB1B IKBKE 153/4885TBK1 392/4885PDPK1 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.